{
  "meta": {
    "title": "Vbd_Arboviral_Viral_Infections",
    "url": "https://brainandscalpel.vercel.app/vbd-arboviral-viral-infections-d0cc3a1a.html",
    "scrapedAt": "2025-11-29T18:34:49.089Z"
  },
  "questions": [
    {
      "id": 1567,
      "choices": [
        {
          "id": 6263,
          "text": "<p><span style=\"font-size:12pt;\">Pregnancy</span></p>"
        },
        {
          "id": 6264,
          "text": "<p><span style=\"font-size:12pt;\">HIV infection- asymptomatic</span></p>"
        },
        {
          "id": 6265,
          "text": "<p><span style=\"font-size:12pt;\">Respiratory infection</span></p>"
        },
        {
          "id": 6266,
          "text": "<p><span style=\"font-size:12pt;\">Malnutrition</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A medical resident is discussing the administration of the measles vaccine with a supervising physician. The conversation focuses on contraindications to vaccination, which are critical for ensuring patient safety. The resident is asked about definitive contraindications for administering the measles vaccine. Which of the following is considered a definitive contraindication for the measles vaccine?</span></p>",
      "unique_key": "Q1913368",
      "question_audio": null,
      "question_video": null,
      "map_id": 34186,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. Pregnancy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A:</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Measles vaccine</strong> is <strong>contraindicated</strong> in <strong>pregnancy</strong>, as the measles vaccine is a <strong>live attenuated vaccine</strong>.&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Contraindications</strong> of <strong>measles</strong> vaccine -&nbsp;<strong>Allergy to measles virus, gelatin</strong> or <strong>neomycin</strong>, <strong>reduced immunity</strong> due to <strong>cancer</strong>, <strong>concurrent infection</strong>, or <strong>immunosuppressants</strong> or those taking <strong>monoclonal antibodies.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option&nbsp;B. HIV Infection - Asymptomatic: </strong>Can be <strong>administered to HIV-infected individuals</strong>, especially if they are <strong>asymptomatic</strong> or <strong>not severely immunocompromised</strong>. <strong>Vaccination</strong> should be <strong>considered</strong> after careful<strong> evaluation of the immune status.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;C. Respiratory Infection: Not</strong> a <strong>contraindication,</strong> if the <strong>illness is mild</strong> and <strong>without fever</strong>, vaccination can generally<strong> proceed</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;D. Malnutrition: </strong>Malnutrition<strong>,</strong> particularly in countries where <strong>measles is endemic</strong>, is <strong>not</strong> a <strong>contraindication</strong> to <strong>measles</strong> vaccination. In fact, <strong>vaccination</strong> is crucial in <strong>malnourished</strong> individuals due to their <strong>increased risk </strong>of <strong>severe measles</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Some important pointers regarding vaccine contraindications -&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Vaccines <strong>contraindicated</strong> in <strong>Pregnancy</strong>: All live vaccines <strong>EXCEPT Yellow fever vaccine</strong></span></li><li><span style=\"font-size:12pt;\">Vaccines <strong>contraindicated</strong> in <strong>HIV</strong>:</span><ul><li><span style=\"font-size:12pt;\">Asymptomatic HIV: NONE</span></li><li><span style=\"font-size:12pt;\"><strong>Symptomatic HIV</strong>: <strong>All live vaccines</strong> EXCEPT <strong>MMR, Varicella &amp; Zoster</strong> may be given if required</span></li></ul></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in Immuno-suppression: All live vaccines</span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in Corticosteroid therapy: All live vaccines</span></li><li><span style=\"font-size:12pt;\">Vaccines<strong> contraindicated</strong> in <strong>fever</strong>: <strong>Typhoid vaccines</strong></span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in ARTI/diarrhoea: NONE</span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated together: Yellow fever and Cholera vaccine</span></li><li><span style=\"font-size:12pt;\">Vaccine contraindicated in<strong> Preterm-premature baby</strong> with birth weight &lt; 2 kg: <strong>Hepatitis B</strong></span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in age &lt; 1 year (infants):&nbsp;– Yellow fever vaccine,&nbsp;Meningococcal vaccine,&nbsp;Pneumococcal vaccine</span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in age &lt; 2 year (infants):&nbsp;– Meningococcal vaccine,&nbsp;Pneumococcal vaccine,&nbsp;Typhoid vaccines</span></li><li><span style=\"font-size:12pt;\">Vaccine <strong>contraindicated</strong> in <strong>progressive neurological disease</strong>: <strong>Pertussis vaccine</strong> (Pertussis vaccine IS NOT CONTRAINDICATED IN epilepsy controlled on medications, Cerebral palsy)</span></li><li><span style=\"font-size:12pt;\">Only <strong>absolute contraindication</strong> to <strong>killed vaccines</strong>: Severe <strong>local or general reaction</strong> to a <strong>previous dose</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Measles vaccine</strong> is <strong>definitively</strong> <strong>contraindicated</strong> in <strong>pregnancy.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 729)</strong></span></p>",
      "correct_choice_id": 6263,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1652,
      "choices": [
        {
          "id": 6603,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">One tablet twice a day</span></span></p>"
        },
        {
          "id": 6604,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Two tablets twice a day</span></span></p>"
        },
        {
          "id": 6605,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Three tablets twice a day</span></span></p>"
        },
        {
          "id": 6606,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Four tablets twice a day</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A group of medical residents participating in a public health initiative are tasked with developing a protocol for the administration of cotrimoxazole in pediatric patients. They are focusing on standardizing treatment according to the Integrated Management of Neonatal and Childhood Illnesses (IMNCI) guidelines. The residents are reviewing the dosing guidelines for different age groups and weights. According to the IMNCI guidelines, what is the recommended dosage of pediatric cotrimoxazole tablets for children aged 1 to 5 years with a body weight of 10-19 kg?</span></span></p>",
      "unique_key": "Q8886897",
      "question_audio": null,
      "question_video": null,
      "map_id": 34184,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Three tablets twice a day</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">According to <strong>IMNCI guidelines</strong>, the recommended dosage of <strong>pediatric cotrimoxazole</strong> for children aged <strong>1 to 5 years</strong> weighing between <strong>10-19 kg</strong> is <strong>3 tablets twice</strong> a <strong>day.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. 1 tablet twice a day:</strong> <strong>Incorrect.</strong> This <strong>dosage</strong> is appropriate for <strong>infants &lt;2 months</strong>, weight <strong>3-5 kg.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. 2 tablets twice a day:</strong> <strong>Incorrect</strong>. This <strong>dosage</strong> is <strong>less </strong>than the recommended amount for an <strong>infant 2-12 months</strong>, <strong>weighing </strong>between <strong>6 and 9</strong> <strong>kg </strong>as per <strong>IMNCI guidelines</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. 4 tablets twice a day:</strong> <strong>Incorrect</strong>. This <strong>dosage exceeds</strong> the <strong>recommended</strong> amount for a <strong>child</strong> in the <strong>specified weight </strong>range according to <strong>IMNCI guidelines</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Pediatric Cotrimoxazole Dosage</strong> - (as per age and weight)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture20_RImCV8I.jpg\" style=\"height:832px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref:</u></strong><strong> Park 26<sup>th</sup> edition (page 187)</strong></span></span></p>",
      "correct_choice_id": 6605,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1653,
      "choices": [
        {
          "id": 6607,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce pneumonia mortality in under 5 children to &lt; 3 per 1000 live births</span></span></p>"
        },
        {
          "id": 6608,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce diarrhoea mortality in under 5 children to &lt; 3 per 1000 live births<strong>&nbsp; </strong></span></span></p>"
        },
        {
          "id": 6609,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce incidence of severe pneumonia by 75% as compared to 2010 levels</span></span></p>"
        },
        {
          "id": 6610,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce incidence of severe diarrhoea by 75% as compared to 2010 levels</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A team of medical residents is participating in a global health challenge competition, where they are tasked with developing innovative strategies to achieve the targets set by the Integrated Global Plan for the Prevention and Control of Pneumonia and Diarrhoea by 2025. As part of the challenge, they are given a quiz to test their knowledge of the plan&#39;s objectives. The team needs to identify which of the following objectives for 2025 is not included in the plan. Which goal is NOT a part of the Integrated Global Plan for the Prevention and Control of Pneumonia and Diarrhoea?</span></span></p>",
      "unique_key": "Q1911940",
      "question_audio": null,
      "question_video": null,
      "map_id": 34185,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. Reduce diarrhoea mortality in under 5 children to &lt; 3 per 1000 live births</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>correct Goal</strong> is -&nbsp;<strong>Reduce Diarrhoea mortality</strong> in <strong>Infants &lt; 1 per 1000 LB</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Integrated Global Action Plan</strong> for <strong>Prevention and Control</strong> of&nbsp;<strong>Pneumonia</strong> &amp; <strong>Diarrhoea (GAPPD)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Specific Goals for 2025:</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Reduce Pneumonia mortality</strong> <strong>in Under-five &lt; 3 per 1000 LB</strong>, <strong>Reduce Diarrhoea mortality</strong> in Infants <strong>&lt; 1 per 1000 LB</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Reduce Incidence of Severe Pneumonia in Under- </strong>fives by <strong>75%</strong> (2010 baseline)</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Reduce Incidence of Severe Diarrhoea in Under</strong>-fives by <strong>75% </strong>(2010 baseline)</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Reduce</strong> Global no. of <strong>Stunted Under-fives</strong> by <strong>40%</strong> (2010 baseline)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; Coverage targets:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125739.png\" style=\"height:543px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Integrated Global Action Plan</strong> for <strong>Prevention</strong> and <strong>Control of&nbsp;Pneumonia</strong> &amp; <strong>Diarrhoea </strong>(GAPPD)&nbsp;Specific Goals for <strong>2025</strong> are&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce <strong>Pneumonia</strong> mortality in Under-five <strong>&lt; 3 per 1000 LB</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce <strong>Diarrhoea </strong>mortality in Infants <strong>&lt; 1 per 1000 LB</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce Incidence of <strong>Severe Diarrhoea</strong> in Under-fives by <strong>75%</strong> (2010 baseline)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce Incidence of <strong>Severe Pneumonia</strong> in Under-fives by <strong>75%</strong> (2010 baseline)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce <strong>Global no. of Stunted</strong> Under-fives by <strong>40% </strong>(2010 baseline)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 189)</strong></span></span></p>",
      "correct_choice_id": 6608,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1696,
      "choices": [
        {
          "id": 6779,
          "text": "<p><span style=\"font-size:12pt;\">Replacement of tOPV with bOPV.</span></p>"
        },
        {
          "id": 6780,
          "text": "<p><span style=\"font-size:12pt;\">Replacement of OPV with IPV.</span></p>"
        },
        {
          "id": 6781,
          "text": "<p><span style=\"font-size:12pt;\">Both</span></p>"
        },
        {
          "id": 6782,
          "text": "<p><span style=\"font-size:12pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a postgraduate teaching seminar focused on infectious diseases, a junior resident is presenting on the various strategies employed in the global initiative to eradicate polio. A significant portion of the presentation is dedicated to discussing 'the switch' – a pivotal moment in the history of polio eradication efforts. This strategy has played an essential role in the worldwide campaign to halt the transmission of all poliovirus types. The resident aims to explain the specifics of 'the switch' to the attendees, emphasizing its impact on the global fight against polio.&nbsp;In the global efforts to eradicate polio, what specifically does 'the switch' refer to?</span></p>",
      "unique_key": "Q2221629",
      "question_audio": null,
      "question_video": null,
      "map_id": 34181,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. Replacement of tOPV with bOPV.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>first stage of OPV</strong> <strong>withdrawal </strong>involved a <strong>global synchronized cessation</strong> of <strong>tOPV </strong>use between <strong>18th April and 1st May 2016</strong>, <strong>replacing tOPV with bOPV</strong> containing only <strong>type 1 and 3 polioviruses</strong> and <strong>withdrawing OPV type 2</strong> from <strong>all immunization</strong> activities called “<strong>the Switch</strong>”. <strong>Once switch</strong> is made, <strong>tOPV</strong> will <strong>no </strong>longer be <strong>used </strong>anywhere in the <strong>world</strong> and <strong>manufacturers</strong> will <strong>no</strong> <strong>longer</strong> supply <strong>tOPV.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:14px;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</span></p><p><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture23.jpg\" alt=\"\" width=\"300\" height=\"315\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>“SWITCH”</strong> - <strong>Replacing Trivalent OPV</strong> with <strong>Bivalent OPV.</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Concept: An important transition in the <strong>vaccines</strong> used to <strong>eradicate polio</strong> requires removal of <strong>all OPVs</strong> in the <strong>long‑term</strong> to <strong>eliminate rare risks</strong> of <strong>VAPP </strong>and <strong>cVDPV</strong></span></li><li><span style=\"font-size:12pt;\">Strategy:&nbsp;</span><ul><li><span style=\"font-size:12pt;\"><strong>Withdrawal</strong> of <strong>OPVs</strong> must occur in a <strong>globally synchronized</strong> manner, <strong>starting </strong>in <strong>April 2016</strong> with a <strong>switch from trivalent OPV</strong> (tOPV) to <strong>bivalent OPV</strong> (bOPV), <strong>removing</strong> the <strong>type 2</strong> component (OPV2) <strong>from immunization</strong> programs of countries.</span></li><li><span style=\"font-size:12pt;\">Preparation for the <strong>removal of OPVs</strong> also includes the <strong>introduction </strong>of at least <strong>one dose of IPV</strong> in <strong>routine immunization programs</strong> in <strong>all countries</strong> by end of <strong>2015.</strong></span></li></ul></li><li><span style=\"font-size:12pt;\">Indian “Switch”:</span><ul><li><span style=\"font-size:12pt;\"><strong>National Switch Date</strong>: <strong>April 25, 2016</strong></span></li><li><span style=\"font-size:12pt;\"><strong>National Validation Day</strong>: <strong>May 09, 2016</strong> (India to be declared free of tOPV)</span></li><li><span style=\"font-size:12pt;\"><strong>Destroy</strong> all <strong>tOPV</strong> on/after <strong>25th April 2016</strong></span></li><li><span style=\"font-size:12pt;\"><strong>IPV </strong>in 6 states (UP, Bihar, Madhya Pradesh, Gujarat, Punjab, Assam): <strong>One Intramuscular</strong> dose given along <strong>with 3rd dose</strong> of <strong>DTP at 14 weeks</strong></span></li><li><span style=\"font-size:12pt;\"><strong>&nbsp;IPV</strong> in other states (Orissa, Andhra Pradesh, Telangana, Tamil Nadu, Kerala, Karnataka, Maharashtra, Puducherry): <strong>Fractional dose</strong> (<strong>0.1 mL</strong> instead of 0.5 mL) <strong>by intradermal</strong> route <strong>at 6 and 14 weeks</strong> from <strong>April, 2016</strong> <strong>(Right deltoid upper arm)</strong></span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">A critical step in <strong>eradication of Polio</strong>, is <strong>‘the switch’</strong> which refers to -&nbsp;<strong>Replacement of tOPV</strong> with <strong>bOPV.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 236)</strong></span></p>",
      "correct_choice_id": 6779,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1705,
      "choices": [
        {
          "id": 6815,
          "text": "<p><span style=\"font-size:12pt;\">Intramuscular</span></p>"
        },
        {
          "id": 6816,
          "text": "<p><span style=\"font-size:12pt;\">​ Intradermal</span></p>"
        },
        {
          "id": 6817,
          "text": "<p><span style=\"font-size:12pt;\">Subcutaneous</span></p>"
        },
        {
          "id": 6818,
          "text": "<p><span style=\"font-size:12pt;\">Oral</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In an immunization clinic, a junior resident in community medicine is preparing for a training session with interns. The focus is on educating them about the National Immunisation Schedule, specifically the correct administration routes and techniques for various vaccines. An important part of this session is the fractional Inactivated Polio Vaccine (fIPV), a key vaccine in polio eradication efforts. The resident needs to ensure that the interns understand the specific route of administration for fIPV as per the National Immunisation Schedule, as this knowledge is crucial for effective vaccine delivery and patient care. According to the NIS, what is the recommended route of administration for fractional Inactivated Polio Vaccine (fIPV)?</span></p>",
      "unique_key": "Q2703012",
      "question_audio": null,
      "question_video": null,
      "map_id": 34182,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. Intradermal</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">IPV Vs Fractionated IPV (fIPV)</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-124535.png\" alt=\"\" width=\"1000\" height=\"641\"></p><p><span style=\"font-size:14px;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</span></p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Fractionated inactivated Polio Vaccine</strong> (fIPV) is administered <strong>intradermally </strong>according to the <strong>National Immunisation Schedule.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">NEW National Immunization Schedule (NIS) 2023-24</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125017.png\" alt=\"\" width=\"1000\" height=\"1129\"></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Note - <strong>Age Limits</strong> for <strong>Delayed Immunization</strong> in <strong>NIS, India</strong> for <strong>fIPV is 1 year.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>fIPV</strong> is <strong>fractionated intradermal</strong> at <strong>6 weeks, 14 weeks &amp; 9 months</strong> (<strong>3 doses</strong>).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 237)</strong></span></p>",
      "correct_choice_id": 6816,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1712,
      "choices": [
        {
          "id": 6841,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Classical signs of cholera is absent</span></span></p>"
        },
        {
          "id": 6842,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Higher rates of carriers</span></span></p>"
        },
        {
          "id": 6843,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">More number of secondary cases</span></span></p>"
        },
        {
          "id": 6844,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chick erythrocyte agglutination is positive</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident specializing in infectious diseases is preparing a presentation on cholera, focusing on the differences between the El Tor and classical biotypes of Vibrio cholerae. Understanding these differences is important for epidemiology, clinical presentation, and public health response. The resident aims to clarify common misconceptions and highlight key characteristics that are similar or different between these two biotypes. Which of the following characteristics is NOT a difference between cases of cholera caused by the El Tor biotype and the classical biotype of Vibrio cholerae?</span></span></p>",
      "unique_key": "Q3228967",
      "question_audio": null,
      "question_video": null,
      "map_id": 34183,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. More number of secondary cases</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>El tor</strong> type:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Higher incidence</strong> of <strong>mild and asymptomatic infections.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Classical</strong> picture <strong>of cholera</strong> may <strong>not</strong> be seen often.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Fewer </strong>secondary cases in <strong>affected families.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Chronic carriers</strong> are <strong>common.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>More resistant</strong> than classical cholera.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some important Pointers related to Cholera -</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Cholera</strong> is an <strong>acute diarrhoel disease</strong> caused by <strong>Vibrio cholera.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Vibrio cholerae</strong>: &lsquo;<strong>Gram-negative bacterium&rsquo;</strong> that produces <strong>cholera toxin</strong> (enterotoxin), which act on <strong>c-AMP system</strong> of <strong>mucosal cells</strong> of epithelium lining of the <strong>small intestine</strong> (to cause <strong>massive diarrhea -</strong>&nbsp;<strong>Rice-watery diarrhoea</strong>)</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Classical biotype</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>El Tor biotype</strong> [Serotypes: <strong>Ogawa</strong> (Earlier MC in <strong>India</strong>), <strong>Inaba</strong> and <strong>Hikojima</strong>]</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Recently <strong>El Tor Hybrid</strong> subtype has become <strong>MC in India</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period: <strong>1&ndash;2 days</strong> (Few hours&ndash;5 days)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reservoir: <strong>Human beings only</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Essentials for <strong>treatment of cholera</strong>: <strong>Water and electrolyte replacement</strong> (<strong>ORS</strong>)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Father of Public Health: Cholera</strong> (although some regard John Snow as the same)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most susceptible <strong>blood group to cholera</strong>: <strong>Blood group O</strong> (&gt;B &gt; A &gt; AB)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>History of cholera</strong>: &ndash; <strong>John Snow</strong> (1813-1858): Found the <strong>link</strong> between <strong>cholera and contaminated drinking water</strong> (1854 using Spot maps)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Robert Koch</strong> identified <strong>V. cholerae</strong> with a <strong>microscope</strong> as the <strong>bacillus</strong> causing the <strong>disease</strong> (<strong>1885</strong>).</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;<strong>Cholera morbus</strong>: Used in <strong>19th</strong> and <strong>early 20th centuries</strong> for both <strong>non-epidemic cholera</strong> and other <strong>gastrointestinal diseases</strong> (sometimes epidemic) that <strong>resembled cholera.</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Important Pointers related to El tor type Cholera</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Higher incidence</strong> of <strong>mild and asymptomatic infections.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Classical picture of cholera</strong> may <strong>not</strong> be seen often.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Fewer secondary cases</strong> in <strong>affected families</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Chronic carriers</strong> are <strong>common.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>More resistant</strong> than classical cholera.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 680)</strong></span></span></p>",
      "correct_choice_id": 6843,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}